Comparative Pharmacology
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE INTENSOL versus MELLARIL S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE INTENSOL versus MELLARIL S.
CHLORPROMAZINE HYDROCHLORIDE INTENSOL vs MELLARIL-S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorpromazine is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also exhibits antagonism at serotonin 5-HT2, histamine H1, alpha-1 adrenergic, and muscarinic receptors, contributing to its sedative, antiemetic, and hypotensive effects.
Thioridazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, also exhibiting alpha-adrenergic blockade and anticholinergic effects.
Oral: 25-50 mg 2-3 times daily, up to 1000 mg/day in severe psychosis. IM: 25-50 mg every 1-4 hours until controlled, then switch to oral.
Initial 50-100 mg orally 3 times daily, titrate to 200-600 mg/day in divided doses; maximum 800 mg/day for severe psychosis.
None Documented
None Documented
15-30 hours; prolonged in elderly and hepatic impairment; active metabolites (e.g., 7-hydroxychlorpromazine) have longer half-lives (up to 12-24 hours)
Terminal elimination half-life: 10–20 hours (mean ~15 hours). Clinical context: Steady-state achieved within 4–5 days; allows once-daily or twice-daily dosing.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (~20-30%)
Primarily renal (approximately 70%) as metabolites (sulfoxides and glucuronides); about 30% excreted in feces via bile. Less than 1% excreted unchanged.
Category C
Category C
Antipsychotic
Antipsychotic